Biotech News

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid (PYPD)PolyPid2026-02-11 12:30 ESTEarnings

The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the E nd of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel,

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

PYPDPolyPid2026-08-12 11:30 EST

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Stock data

Close: 4.77 USD
Market cap: 93.38M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Related news

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results